In support of these findings, studies in distinct cancer models confirm a role of IGF2BP1 in promoting additional cancer hallmark pathways, including MYC/MYCN-driven gene expression demonstrated in ovarian cancer (Köbel et al., 2007), liver cancer (Gutschner et al., 2014; Huang H. et al., 2018) and neuroblastoma (Bell et al., 2015), as well as KRAS-driven signaling in lung adenocarcinoma (Rosenfeld et al., 2019). Here, IGF2BP1 is linked to cancer.